Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from NVS

Novartis' Breast Cancer PI3K Drug, Scores FDA Approval For Ultra-Rare Indication

The FDA has granted accelerated approval to Novartis AG's (NYSE: NVS) Vijoice (alpelisib) for patients 2 years of age and older with severe manifestations of PIK3CA-Related Overgrowth Spectrum (PROS) who require systemic therapy.

Novartis Highlights Four-Year Efficacy, Safety Data On Kesimpta In Multiple Sclerosis

Novartis Highlights Four-Year Efficacy, Safety Data On Kesimpta In Multiple Sclerosis

Novartis AG (NYSE:NVS) announced new long-term data from the Phase 3 ASCLEPIOS 1/2 trials and the ALITHIOS open-label extension of Kesimpta (ofatumumab) in multiple sclerosis. The data demonstrated long-term efficacy and safety of Kesimpta with continued reduced risk of disability worsening in relapsing multiple sclerosis following up to four years of treatment. Kesimpta…

5 Healthcare Stocks Likely to Withstand a Recession

5 Healthcare Stocks Likely to Withstand a Recession

The healthcare industry has attracted massive investor interest since the onset of the COVID-19 pandemic and could remain in the limelight as COVID cases surge again and necessitate the need for more COVID shots. In addition, the healthcare sector is known to withstand recessions relatively well. So, with several analysts…

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Novartis Receives Positive CHMP Opinion For Kymriah In Follicular Lymphoma, Jakavi In GvHD

The European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending approval of Novartis AG's (NYSE: NVS)

Ex on the Beach's Declan Doyle's showbiz past before romance with Geordie Shore's Nathan

Barber and model Declan Doyle, who is dating Geordie Shore star Nathan Henry, has just popped up on Ex on the Beach - but fans of the show may be wondering where they've seen him before

FDA Approves Novartis' Pluvicto As First Targeted Radioligand Therapy For Prostate Cancer

The FDA approved Novartis AG's (NYSE:NVS) Pluvicto (lutetium Lu 177 vipivotide tetraxetan) to treat patients with a type of advanced prostate cancer that has spread to other parts of the body. Pluvicto is a targeted radioligand therapy for adult patients who have already undergone other anticancer treatments. The company said it had submitted…

Novartis Suspends Some Investment, Business Activities In Russia

Novartis AG (NYSE:NVS) will suspend capital investments, media advertising, and other promotional activities in Russia but remain committed to providing access to its medicine there. "Novartis condemns the war in Ukraine," it said in a statement, adding that "while we remain committed to providing access to our medicine in Russia, we responsibly…

inkl

Read news from The Economist, FT, and more,
with one subscription

Novartis's Data Reinforces Age-Appropriate Development With Zolgensma Gene Therapy Study

Novartis's Data Reinforces Age-Appropriate Development With Zolgensma Gene Therapy Study

Novartis AG (NYSE:NVS) announced new data from the completed Phase 3 SPR1NT study of Zolgensma (onasemnogene abeparvovec), a one-time treatment for spinal muscular atrophy (SMA). The data demonstrated that children with three copies of the SMN2 backup gene who were treated presymptomatically achieved age-appropriate motor milestones, including standing and walking. In addition, a descriptive posthoc…

NEJM Publication Shows Novartis' Kisqali With Longest Median Overall Survival In Breast Cancer Setting

NEJM Publication Shows Novartis' Kisqali With Longest Median Overall Survival In Breast Cancer Setting

The New England Journal of Medicine (NEJM) published data from Phase 3 MONALEESA-2 trial of Novartis AG's (NYSE:NVS) Kisqali (ribociclib) plus letrozole demonstrating a statistically significant improvement in overall survival. MONALEESA-2 overall survival data were first presented at the European Society for Medical Oncology Congress in September 2021. The NEJM publication includes additional analyses substantiating the longest median…

Voyager Therapeutics Shares Jump On Novartis Option Agreement For Gene Therapy Programs

Voyager Therapeutics Shares Jump On Novartis Option Agreement For Gene Therapy Programs

Novartis AG (NYSE: NVS) has

5 Defensive Stocks to Own for Consistent Dividends and Stable Earnings

5 Defensive Stocks to Own for Consistent Dividends and Stable Earnings

Concerns over the Russia-Ukraine war and high inflation have significantly affected the global equity markets lately. As the stock market is expected to remain highly volatile in the coming weeks, it could be wise to bet on defensive stocks Walmart (WMT), Novartis (NVS), Merck & Co. (MRK), GlaxoSmithKline (GSK), and…

Molecular Partners, Novartis Submit Emergency Use Authorization Request For Ensovibep For COVID-19

Molecular Partners, Novartis Submit Emergency Use Authorization Request For Ensovibep For COVID-19

Molecular Partners AG (NASDAQ: MOLN) and its partner Novartis AG (NYSE: NVS), have

Recap: Novartis Q4 Earnings

Recap: Novartis Q4 Earnings

Novartis (NYSE:NVS) reported its Q4 earnings results on Wednesday, February 2, 2022 at 08:00 AM. Here's what investors need to know about the announcement.

Novartis Expects FY22 Sales, Profit Growth; Sandoz Review Continues

Novartis Expects FY22 Sales, Profit Growth; Sandoz Review Continues

Novartis AG (NYSE: NVS) reported a Q4 net income of $16.31 billion, up from $2.1 billion the previous year,

Get all your
news in one place.

100's of premium titles.
One news app.

Carlyle, Blackstone Mull $25B Buyout For Novartis' Sandoz Arm: Report

Investor groups Blackstone and Carlyle could join forces on a massive $25 billion bid for Novartis AG's unit (NYSE: NVS) Sandoz,

1 2 3 4

People

Justin Timberlake

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

European Medicines Agency

Novo Nordisk AS

inkl

Read news from The Economist, FT, and more,
with one subscription

Places

355,029 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play